Acyclovir pharmacokinetics in plasmapheresis.

J Clin Apher

Service des Maladies Infectieuses et Tropicales, Hopital du Bocage, Dijon, France.

Published: March 1990

During experimental treatment of human immunodeficiency virus (HIV-1) infection using high doses of acyclovir (ACV) (600 mg IV every 8 h), cyclosporin, and several courses of plasmapheresis (PE) (60 ml/kg), ACV pharmacokinetics in three patients have been measured. The results with or without PE were not significantly different: half-time of elimination 3 vs. 2.3 h, volume of distribution 1.8 vs. 1.14 liter/kg, and total clearance 404 vs. 314 ml/min. The clearance and the fraction of elimination due to PE were 5.27 ml/min and 2.5%, respectively. These findings suggest that supplemental doses of ACV are not needed when plasmapheresis is performed.

Download full-text PDF

Source

Publication Analysis

Top Keywords

acyclovir pharmacokinetics
4
pharmacokinetics plasmapheresis
4
plasmapheresis experimental
4
experimental treatment
4
treatment human
4
human immunodeficiency
4
immunodeficiency virus
4
virus hiv-1
4
hiv-1 infection
4
infection high
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!